Indaptus Therapeutics is trading 10.88% down at $2.54, with no clear reason identified for the September 30 decline. - Shares fell 13.37% on September 29 and 14.55% on September 28, extending the decline. - The $24 million private placement was announced earlier in September and does not establish a cause for this move. - Major indices are slightly higher in the supplied market context, offering no clear broad-market explanation.